NasdaqCM:VKTX
NasdaqCM:VKTXBiotechs

Why Viking Therapeutics (VKTX) Is Up 6.1% After VK2735 Phase 2 Obesity Data And Phase 3 Progress

Earlier in January 2026, Viking Therapeutics reported peer-reviewed Phase 2 VENTURE trial results for its dual GLP‑1/GIP agonist VK2735, showing statistically significant weight loss of up to 14.7% over 13 weeks with generally mild to moderate side effects. With Phase 3 VANQUISH-1 and VANQUISH-2 trials now underway and enrollment largely completed, Viking is moving VK2735 toward longer-term efficacy and safety evaluation in both obesity and type 2 diabetes populations. We’ll now examine how...
NasdaqGM:WLDN
NasdaqGM:WLDNProfessional Services

Can Rising Data Center Energy Demands Turn Willdan Group’s Commercial Business Into a Core Profit Driver (WLDN)?

Recent commentary highlighted that Willdan Group is seeing increased demand from state and local governments, utilities, and commercial customers for energy optimization and infrastructure efficiency services, including projects linked to data center energy use. An important angle is that Willdan’s commercial segment, currently a smaller share of revenue, is being highlighted as a potential growth engine as more companies seek to curb rising energy costs. We’ll now examine how this increased...
NasdaqGS:CALM
NasdaqGS:CALMFood

Why Cal-Maine Foods (CALM) Is Down 5.3% After Q2 Miss and Buyback Completion - And What's Next

Cal-Maine Foods reported past second-quarter 2025 results showing sales of US$769.5 million and net income of US$102.76 million, alongside a US$0.72 per-share cash dividend under its variable policy and completion of a US$124.84 million share repurchase program covering 2.87% of shares. The company pointed to the normalization of egg prices after last year’s supply shock while leaning more on specialty eggs and prepared foods to support earnings resilience. We’ll now examine how the earnings...
NYSE:USPH
NYSE:USPHHealthcare

U.S. Physical Therapy (USPH) Is Up 8.1% After 17.3% Revenue Gain And Upbeat Analyst Sentiment

In recent days, U.S. Physical Therapy, Inc. has drawn heightened investor attention as revenue rose 17.30%, supported by what analysts describe as compelling growth prospects and a robust operating model. What stands out is the combination of this strong revenue performance with largely positive analyst sentiment, which together underpin a reinforced confidence in the company’s long-term business trajectory. With strong analyst enthusiasm around its growth prospects now in focus, we’ll...